2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
430
Lymphoma, Large B-Cell, Diffuse
97
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Follicular
81
Recurrence
72
Lymphoma
62
Lymphoma, Mantle-Cell
59
Neoplasms, Plasma Cell
58
Lymphoma, B-Cell, Marginal Zone
47
Lymphoma, Non-Hodgkin
46
Leukemia, Myeloid, Acute
34
Leukemia
32
Neoplasms
24
Myelodysplastic Syndromes
24
Lymphoma, B-Cell
24
Waldenstrom Macroglobulinemia
18
Hodgkin Disease
18
Smoldering Multiple Myeloma
17
Lymphoma, T-Cell, Peripheral
16
Burkitt Lymphoma
14
Hematologic Diseases
13
Lymphoma, T-Cell, Cutaneous
12
Lymphoma, T-Cell
12
Prostatic Neoplasms
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Sezary Syndrome
10
Mycosis Fungoides
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Large-Cell, Anaplastic
9
Leukemia, Myelomonocytic, Chronic
9
Interventions
Cyclophosphamide
14
Dexamethasone
13
Vincristine
11
Cytarabine
11
Methotrexate
9
venetoclax
7
Inotuzumab Ozogamicin
7
Doxorubicin
7
pegaspargase
6
merphos
6
blinatumomab
6
Prednisone
6
dexamethasone acetate
5
dexamethasone 21-phosphate
5
Mercaptopurine
5
Calcium Dobesilate
5
prednylidene
4
deltacortene
4
azathiopurine
4
auricularum
4
Specimen Handling
4
Leucovorin
4
Asparaginase
4
Thioguanine
3
Rituximab
3
N,N-dicyclohexyl-isoborneol-10-sulfonamide
3
Methylprednisolone
3
fludarabine
2
calaspargase pegol
2
asparaginase erwinia chrysanthemi recombinant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
Lenalidomide
×
Clear all
NCT01116193
2017-09-14
RV-405 LAL
Institut de Cancérologie de la Loire
Phase 2
Completed
10 enrolled